This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.01009-06v1 51/5/1596    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bultmann, H. Articles by Brandt, C. R. Search for Related Content PubMed PubMed Citation Articles by Bultmann, H. Articles by Brandt, C. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2007, p. 1596-1607, Vol. 51, No. 5
0066-4804/07/$08.00+0     doi:10.1128/AAC.01009-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Addition of a C-Terminal Cysteine Improves the Anti-Herpes Simplex Virus Activity of a Peptide Containing the Human Immunodeficiency Virus Type 1 TAT Protein Transduction Domain

Department of Ophthalmology and Visual Sciences,¹ Program in Cell and Molecular Biology,² Department of Medical Microbiology and Immunology, University of Wisconsin—Madison, Madison, Wisconsin 53706³

Received 12 August 2006/ Returned for modification 16 October 2006/ Accepted 16 January 2007

Previous studies have shown that peptides containing the protein transduction domain (PTD) of the human immunodeficiency virus tat protein (GRKKRRQRRR) were effective inhibitors of herpes simplex virus type 1 (HSV-1) entry (H. Bultmann and C. R. Brandt, J. Biol. Chem. 277:36018-36023, 2002). We now show that the addition of a single cysteine residue to the C terminus of the TAT PTD (TAT-C peptide) improves the antiviral activity against HSV-1 and HSV-2. The principle effect of adding the cysteine was to enable the peptide to inactivate virions and to induce a state of resistance to infection in cells pretreated with peptide. The TAT-C peptide acted extracellularly, immediately blocked entry of adsorbed virus, prevented VP16 translocation to the nucleus, and blocked syncytium formation and cell-cell spread. Thus, TAT-C peptides are fusion inhibitors. The induction of the resistance of cells to infection was rapid, recovered with a half-life of 5 to 6 h, and could be reinduced by peptide treatment. TAT-C bound to heparan sulfate but was a poor competitor for viral attachment. The antiviral activity depended on the net positive charge of the peptide but not on chirality, and a free sulfhydryl group was not essential for antiviral activity because TAT-C dimers were at least as effective as monomers. The unique combination of antiviral activities and low toxicity combine to make TAT-C a strong candidate for further development as a drug to block HSV infection.

Published ahead of print on 29 January 2007.

This article has been cited by other articles:

• Akkarawongsa, R., Potocky, T. B., English, E. P., Gellman, S. H., Brandt, C. R. (2008). Inhibition of Herpes Simplex Virus Type 1 Infection by Cationic {beta}-Peptides. Antimicrob. Agents Chemother. 52: 2120-2129 [Abstract] [Full Text]